Investment

Features

Pro Tools for Pro Traders

Uncover the powerful trading features

Pro Features

Pluang Web Trading

Leverage

Built for Investors

Experience investing with simplified features

Pockets

Recurring Buy

USD Yield

Pluang Cuan

Fees

Safety

Academy

Latest for You

Get up-to-date financial news and investing tips & information

Blog

Find various tips & information to become a knowledgeable investor

News and Analysis

Read the latest information about finance and investment

Learn

Become a smarter investor by learning the basics of investing

Glossary

Learn investment terms to understand investing better

Promo & Referral

Discover exclusive opportunities to level up your investments

Investment Clubs (Coming Soon)

Join hands with like-minded investors to grow wealth together

Press (Coming Soon)

Stay updated with our latest news and media coverage

Support

About Us

Contact

Ask

Career

Tax Reporting Guide

Pluang+

BridgeBio Pharma Inc (BBIO) Stock Price Today

Overview

Financial

Technicals

Analysis

Corporate Action

About

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Technical Indicators

Overall Summary

Bearish (8)

Neutral (10)

Bullish (9)

Performance

BBIO ROI

-6.17%

% from 52W High

-38.98%

$26.78

52W Low: $23

24 Jun 2024

52W High: $43.89

27 Dec 2023

News

Globe Newswire

3mo

BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference

Globe Newswire

4mo

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

Globe Newswire

4mo

BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024

Globe Newswire

4mo

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Globe Newswire

4mo

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting

US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions